Drugs / Autologous CD19-targeting CAR T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02963038 | Jun 2016 → Jun 2017 | lymphoid leukemia, lymphoma | Hebei Senlang Biotechnology Inc., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous CD19-targeting CAR T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02963038 ↗ |
| Modality | Cell therapy | “Autologous T cells will be gene engineered with the CAR gene using a lentivirus vector.” NCT02963038 ↗ |
| Target | CD19 | “Chimeric antigen receptor (CAR) T cells targeting CD19” NCT02963038 ↗ |